194 related articles for article (PubMed ID: 19448135)
1. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
Subramanian M; Low M; Locuson CW; Tracy TS
Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
[TBL] [Abstract][Full Text] [Related]
2. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
4. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
5. Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.
Bostick CD; Hickey KM; Wollenberg LA; Flora DR; Tracy TS; Gannett PM
Drug Metab Dispos; 2016 May; 44(5):741-9. PubMed ID: 26961240
[TBL] [Abstract][Full Text] [Related]
6. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.
Siu YA; Hao MH; Dixit V; Lai WG
Drug Metab Pharmacokinet; 2018 Oct; 33(5):219-227. PubMed ID: 30219715
[TBL] [Abstract][Full Text] [Related]
8. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
Crespi CL; Miller VP
Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
[TBL] [Abstract][Full Text] [Related]
9. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
10. Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes.
Hazai E; Kupfer D
Drug Metab Dispos; 2005 Jan; 33(1):157-64. PubMed ID: 15486075
[TBL] [Abstract][Full Text] [Related]
11. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
[TBL] [Abstract][Full Text] [Related]
12. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
13. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
14. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
[TBL] [Abstract][Full Text] [Related]
15. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
17. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
19. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Schmider J; Greenblatt DJ; Fogelman SM; von Moltke LL; Shader RI
Biopharm Drug Dispos; 1997 Apr; 18(3):227-40. PubMed ID: 9113345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
